In this episode of Baby Tribe Shorts, Afif and Anne tackle the anxiety caused by recent headlines linking paracetamol use in pregnancy with autism, ADHD and intellectual disability. They walk through a major Lancet systematic review and meta-analysis, explaining why the best-quality evidence, especially sibling comparison studies, does not support a causal link between paracetamol use in pregnancy and these neurodevelopmental outcomes.

The episode also explains why paracetamol remains the recommended first-line option for pain and fever in pregnancy, why untreated fever can itself be harmful, and why earlier studies may have suggested a risk because of confounding, recall bias and the reasons people take medication in the first place. The key message for parents is clear: use paracetamol when needed, at recommended doses, and don’t let fear-driven headlines make pregnancy harder than it already is.

https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00211-0/fulltext

In this episode of Baby Tribe Shorts, Afif and Anne take a closer look at one of the most influential obstetric studies of the last decade: the ARRIVE trial.

The trial is often used in conversations about elective induction at 39 weeks, especially for low-risk first-time mothers. But what did it actually show? Did induction improve outcomes for babies? Did it really reduce C-section rates? And what happens when the findings of a carefully controlled clinical trial are applied to busy real-world maternity units?

Afif and Anne break down the design of the trial, including who was included, how the induction and expectant management groups were managed, and why the distinction between internal validity and external validity matters. They discuss the key findings, including the lack of significant difference in neonatal outcomes, the reported reduction in C-section rates, and the importance of patience, staffing, careful selection, and clinical context when translating research into practice.

This is not an anti-induction episode. It is an episode about nuance. Induction at 39 weeks may be a reasonable option for some women, but the ARRIVE trial does not mean that every low-risk pregnancy should automatically end at 39 weeks. As always, the real question is not just “what did the study show?” but “does this apply to this person, in this hospital, with these resources, and these priorities?”

Link to Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1800566